Thomas M Habermann

Oct 8, 2024 | nature.com | Melissa Hopper |Abigail R. Dropik |Janek S. Walker |Jordan E. Krull |Matthew J. Maurer |Zhi-Zhang Yang | +4 more

AbstractThis study sheds light on the pivotal role of the oncoprotein DEK in B-cell lymphoma. We reveal DEK expression correlates with increased tumor proliferation and inferior overall survival in cases diagnosed with low-grade B-cell lymphoma (LGBCL). We also found significant correlation between DEK expression and copy number alterations in LGBCL tumors, highlighting a novel mechanism of LGBCL pathogenesis that warrants additional exploration.

Aug 28, 2024 | nature.com | Saurabh Zanwar |Jonas Paludo |Ronald S. Go |Joselle M. Cook |Sikander Ailawadhi |Thomas M Habermann | +10 more

An under-recognized source of bleeding in Waldenström macroglobulinemia (WM) is the development of an acquired von Willebrand syndrome (AVWS) [1]. In WM, the von Willebrand Factor (vWF) glycoprotein can be degraded due to autoantibody destruction, increased shear stress due to hyperviscosity, or sequestered due to adsorption onto malignant cells, leading to the development of AVWS (AVWS-WM) [1, 2].

Jun 19, 2024 | nature.com | Melissa Hopper |Jordan E. Krull |C. Chris Huang |Matthew J. Maurer |Susan L Slager |Patrizia Mondello | +8 more

AbstractRecent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an integrative multiomic approach to identify a signature at diagnosis that will identify DLBCL at high risk of early clinical failure. Tumor biopsies from 444 newly diagnosed DLBCL were analyzed by WES and RNAseq.

Nov 12, 2023 | nature.com | Jennifer J. Gile |Matthew J. Maurer |Jonas Paludo |Stephen Ansell |Thomas M Habermann |Thomas E Witzig | +4 more

AbstractOver the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult patients with newly diagnosed MCL from 2002 to 2015 were enrolled in a prospective cohort study.

May 16, 2023 | onclive.com | Thomas M Habermann

Thomas M. Habermann, MD, consultant, Division of Hematology, Department of Internal Medicine, professor of medicine, Mayo Clinic, discusses ongoing clinical trials in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). The formal publication of findings from the phase 3 TRIANGLE trial (NCT02858258) are anticipated, and data from the study presented at the 2022 ASH Annual Meeting could potentially be practice changing, Habermann says.